A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC
Status:
Recruiting
Trial end date:
2023-12-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of dabrafenib in combination
with trametinib in Chinese patients with BRAF V600E mutation-positive metastatic Non-Small
Cell Lung Cancer. The general study design has been discussed and agreed with Chinese Health
Authority and is applying a similar design used for global pivotal phase II study
(BRF113928).